In this regard, we speculate that the enhancement of NEDD4L, which leads to the suppression of xCT and activation of ferroptosis pathway may be a potential therapeutic target for ESCC patients. The gene discussed is NEDD4L; the disease is esophageal squamous cell carcinoma.